Syros Pharmaceuticals, Inc. (SYRS)
Syros Pharmaceuticals, Inc. operates as a biopharmaceutical firm primarily focused on discovering and developing novel therapeutic solutions for various cancers and monogenic (single-gene) diseases. A key strategic aim for the company involves cultivating a robust pipeline of medicines that modulate gene expression. Its leading investigational drug candidates include: Tamibarotene: A selective retinoic acid receptor alpha agonist, currently undergoing Phase III clinical trials for a genetically defined subset of patients with myelodysplastic syndrome, and in Phase II trials for individuals suffering from acute myeloid leukemia. SY-2101: An innovative oral formulation of arsenic trioxide, intended for the treatment of acute promyelocytic leukemia. SY-5609: A cyclin-dependent kinase 7 inhibitor, which is being assessed in a Phase I clinical study involving patients with specific advanced solid tumors. Syros maintains several strategic alliances, notably a research collaboration and option agreement with Incyte Corporation centered on identifying therapeutic targets for myeloproliferative neoplasms. Furthermore, the company has a licensing arrangement with TMRC Co. Ltd. pertaining to the development and commercialization of tamibarotene. Initially incorporated in 2011 as LS22, Inc., the company officially adopted the name Syros Pharmaceuticals, Inc. in August 2012. Its corporate headquarters are located in Cambridge, Massachusetts.
Sector: Biotechnology
Industry: Biotechnology
Syros Pharmaceuticals, Inc.
- 1:10Reverse splitSep 19, 202210 shares → 1
| Period | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
| Revenue | $9.94M | $14.88M | $23.49M | $15.09M | $1.98M | $2.05M | $1.1M | $317K | $317K | $0 | $0 |
| YoY Growth | -33.2% | -36.6% | 55.6% | 661.5% | -3.3% | 86.2% | 247.3% | 0.0% | - | - | - |
| Cost of Revenue | $2.25M | $2.97M | $0 | $0 | $0 | $0 | $1.53M | $0 | $602K | $0 | $0 |
| Gross Profit | $7.68M | $11.91M | $23.49M | $15.09M | $1.98M | $2.05M | -$426K | $317K | -$285K | $0 | $0 |
| Gross Margin | 77.3% | 80.1% | 100.0% | 100.0% | 100.0% | 100.0% | -38.7% | 100.0% | -89.9% | - | - |
| Research and Development | $108.15M | $111.94M | $99.87M | $76.06M | $58.24M | $50.18M | $41.9M | $37.82M | $24.41M | $10.92M | $6.27M |
| Selling, General, and Administrative | $28.28M | $29.3M | $23.04M | $21.32M | $21.48M | $16.16M | $13.89M | $10.46M | $5.73M | $2.51M | $2.37M |
| Other | -$105.66M | -$102.43M | $0 | $0 | $0 | $0 | $676K | $220K | $2K | $4K | $0 |
| Total Operating Expenses | $30.77M | $38.81M | $122.91M | $97.39M | $79.72M | $66.35M | $55.79M | $48.28M | $30.14M | $13.44M | $8.66M |
| Operating Income (EBIT) | -$128.99M | -$135.87M | -$99.42M | -$82.3M | -$77.74M | -$64.3M | -$54.69M | -$47.96M | -$29.82M | -$13.44M | -$8.63M |
| Operating Margin | -1298.2% | -913.1% | -423.3% | -545.3% | -3922.4% | -3136.4% | -4966.9% | -15130.3% | -9406.9% | - | - |
| Interest Expense | $5.13M | $4.13M | $3.91M | $1.79M | $0 | $1K | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $6.82M | $2.13M | $87K | $426K | $2.3M | $2.02M | $0 | $0 | $0 | $0 | $0 |
| Other Income (Expense) | -$35.59M | $41.22M | $12.86M | -$1.74M | $2.3M | $2.02M | $676K | $220K | $2K | $4K | -$32K |
| Income Before Tax (EBT) | -$164.57M | -$94.65M | -$86.56M | -$84.04M | -$75.44M | -$62.28M | -$54.01M | -$47.74M | -$29.82M | -$13.43M | -$8.66M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$164.57M | -$94.65M | -$86.56M | -$84.04M | -$75.44M | -$62.28M | -$54.01M | -$47.74M | -$29.82M | -$13.43M | -$9.26M |
| Net Income Margin | -1656.3% | -636.1% | -368.5% | -556.8% | -3806.2% | -3038.0% | -4905.5% | -15060.9% | -9406.3% | - | - |
| Supplementary Data | |||||||||||
| EPS | -5.81 | -7.49 | -13.84 | -18.25 | -18.76 | -19.07 | -21.26 | -37.60 | -120.45 | -54.25 | -84.47 |
| Diluted EPS | -5.81 | -7.49 | -13.84 | -18.25 | -18.76 | -19.07 | -21.26 | -37.60 | -120.45 | -54.25 | -84.47 |
| Weighted Average OS | 28.33M | 12.63M | 6.25M | 4.61M | 4.02M | 3.27M | 2.54M | 1.27M | 247,557 | 247,557 | 109,619 |
| EBITDA | -$157.19M | -$87.55M | -$79.63M | -$79.21M | -$72.72M | -$60.67M | -$53.16M | -$46.69M | -$29.22M | -$13.18M | -$8.46M |
| EBITDA Margin | -1582.1% | -588.4% | -339.0% | -524.8% | -3668.8% | -2959.8% | -4828.2% | -14728.7% | -9217.0% | - | - |
| Period | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
| Assets | |||||||||||
| Current Assets | |||||||||||
| Cash and Cash Equivalents | $139.53M | $167.47M | $92.3M | $173.98M | $41.44M | $49.89M | $32.2M | $58.59M | $35.91M | $60.39M | $3.8M |
| Short-Term Investments | $0 | $34.84M | $38.07M | $0 | $49.98M | $49.79M | $39.84M | $25M | $0 | $0 | $0 |
| Cash and Short-Term Investments | $139.53M | $202.3M | $130.37M | $173.98M | $91.42M | $99.68M | $72.05M | $83.59M | $35.91M | $60.39M | $3.8M |
| Accounts Receivable | $0 | $1.69M | $2.98M | $2.33M | $20.16M | $0 | $0 | $867K | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $290K | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $5.45M | $7.39M | $0 | $0 | $0 | $638K | $193K | $1.05M | $0 | $0 | $0 |
| Total Current Assets | $144.98M | $211.39M | $136.59M | $178.56M | $114.51M | $101.73M | $73.16M | $85.51M | $36.45M | $60.54M | $3.91M |
| Long-Term Assets | |||||||||||
| Property, Plant & Equipment Net | $19.48M | $24.66M | $27.29M | $29.64M | $31.89M | $3.86M | $3.94M | $4.85M | $4.8M | $881K | $938K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $2.12M | $3.09M | $13.04M | $3.09M | $3.09M | $290K | $290K | $483K | $483K | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $1.59M | $5.35M | $6.03M | $1.97M | $490K | $881K | $1.1M | $482K | $1.9M | $70K | $70K |
| Total Long-Term Assets | $23.19M | $33.09M | $46.35M | $34.69M | $35.47M | $5.03M | $5.33M | $5.82M | $7.18M | $951K | $1.01M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $168.17M | $244.49M | $182.94M | $213.25M | $149.98M | $106.77M | $78.49M | $91.32M | $43.63M | $61.49M | $4.92M |
| Liabilities | |||||||||||
| Current Liabilities | |||||||||||
| Accounts Payable | $11.54M | $6.41M | $3.69M | $3.6M | $5.85M | $3.31M | $2.28M | $2.42M | $5.04M | $928K | $594K |
| Short-Term Debt | $6.67M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $4.33M | $10.18M | $12.21M | $5.74M | $1.93M | $355K | $550K | $0 | $0 | $0 |
| Other Current Liabilities | $6.99M | $9.44M | $9.28M | $5.71M | $6.47M | $11.3M | $7.23M | $4.52M | $284K | $37K | $36K |
| Total Current Liabilities | $36.68M | $30.78M | $31.51M | $28.62M | $23.52M | $19.53M | $12.41M | $9.57M | $7.96M | $1.25M | $910K |
| Long-Term Liabilities | |||||||||||
| Long-Term Debt | $34.56M | $40.65M | $40.26M | $39.55M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $9.88M | $22.64M | $8.28M | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | -$22K | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $61.75M | $24.47M | $3.03M | $19.71M | $0 | $353K | $745K | $1.1M | $1.42M | $1K | $0 |
| Total Long-Term Liabilities | $114.83M | $85.97M | $66.21M | $94.07M | $47.28M | $8.65M | $751K | $1.15M | $1.63M | $1K | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $151.51M | $116.75M | $97.72M | $122.7M | $70.79M | $28.18M | $13.16M | $10.72M | $9.58M | $1.25M | $910K |
| Stockholders' Equity | |||||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $82.01M | $82.01M | $13.27M |
| Common Stock | $26K | $20K | $61K | $56K | $43K | $34K | $26K | $23K | $2K | $1K | $5K |
| Retained Earnings | -$722.81M | -$558.23M | -$463.58M | -$377.02M | -$292.98M | -$217.54M | -$155.27M | -$101.26M | -$53.51M | -$23.7M | -$10.26M |
| Comprehensive Income & Other | $0 | $102K | -$79K | $0 | $24K | -$3K | -$42K | -$9K | -$931K | -$428K | $0 |
| Other Stockholders' Equity | $739.44M | $685.95M | $548.74M | $467.52M | $372.12M | $296.1M | $220.56M | $181.84M | $87.56M | $83.94M | $14.23M |
| Total Equity | $16.66M | $127.74M | $85.22M | $90.55M | $79.18M | $78.59M | $65.32M | $80.6M | $34.05M | $60.24M | $3.97M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $168.17M | $244.49M | $182.94M | $213.25M | $149.98M | $106.77M | $78.49M | $91.32M | $43.63M | $61.49M | $4.88M |
| Supplementary Data | |||||||||||
| Total Debt | $62.08M | $63.57M | $65.19M | $66.21M | $25.92M | $31K | $53K | $221K | $339K | $0 | $0 |
| Net Debt | -$77.45M | -$103.9M | -$27.11M | -$107.77M | -$15.52M | -$49.85M | -$32.15M | -$58.37M | -$35.57M | -$60.39M | -$3.8M |
| Period | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
| Operating Activities | |||||||||||
| Net Income | -$164.57M | -$94.65M | -$86.56M | -$84.04M | -$75.44M | -$62.28M | -$54.01M | -$47.74M | -$29.82M | -$13.43M | -$8.66M |
| Depreciation & Amortization | $2.25M | $2.97M | $3.02M | $3.04M | $2.72M | $1.6M | $1.53M | $1.27M | $602K | $258K | $170K |
| Deferred Income Tax | $0 | $0 | -$16.46M | $326K | -$1.13M | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $10.43M | $11.41M | $10.35M | $10.94M | $9.84M | $6.61M | $4.42M | $4.23M | $3.23M | $937K | $821K |
| Changes in Working Capital: | |||||||||||
| Accounts Receivable | $1.69M | $1.28M | $7K | $19.99M | -$20.16M | $0 | $867K | -$317K | $0 | $0 | $0 |
| Inventory | $0 | -$1.28M | $1.98M | -$2.53M | -$4.36M | $0 | $3.3M | $2.69M | $0 | $0 | $0 |
| Accounts Payable | $5.13M | $2.77M | $48K | -$1.06M | $1.49M | $888K | $141K | -$404K | $2.02M | $334K | $0 |
| Other Working Capital | -$1.77M | -$8.28M | -$12.64M | -$6.35M | $19.54M | $13.5M | -$870K | -$284K | $914K | -$67K | $86K |
| Total Working Capital Change | $5.05M | -$5.52M | -$10.6M | $10.05M | -$3.48M | $14.39M | $3.44M | $1.69M | $2.94M | $267K | $86K |
| Other Non-Cash Items | $37.13M | -$37.27M | $706K | $2.32M | $7.24M | -$642K | -$102K | $10K | $17K | $334K | $394K |
| Net Cash from Operating | -$109.71M | -$123.06M | -$99.54M | -$57.36M | -$60.25M | -$40.31M | -$44.73M | -$40.54M | -$23.03M | -$11.97M | -$7.19M |
| Investing Activities | |||||||||||
| Capital Expenditures | -$272K | -$1.24M | -$1.25M | -$3.34M | -$12.64M | -$1.38M | -$821K | -$2.32M | -$1.18M | -$201K | -$878K |
| Acquisitions | $0 | $0 | $0 | $0 | $110K | $9K | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$50.97M | $0 | -$51.41M | $0 | -$108.21M | -$96.77M | -$41.77M | -$25.02M | $0 | $0 | $0 |
| Sales of Investments | $87.02M | $68.43M | $0 | $50M | $109M | $87.5M | $27M | $0 | $0 | $0 | $0 |
| Other Investing Activities | $1.56M | $68.43M | -$51.41M | $0 | $0 | $9K | -$14.77M | -$25.02M | $0 | $0 | $0 |
| Net Cash from Investing | $37.34M | $67.19M | -$52.65M | $46.66M | -$11.73M | -$10.64M | -$15.59M | -$27.34M | -$1.18M | -$201K | -$878K |
| Financing Activities | |||||||||||
| Debt Repaid | $65K | $291K | $265K | -$39.38M | $205K | $50K | $168K | $135K | $50K | - | - |
| Common Stock Issuance | $43.27M | $119.76M | $70.34M | $102.27M | $61.18M | $68.51M | $32.31M | $50.48M | -$228K | $15K | $0 |
| Common Stock Repurchases | $0 | -$81K | $0 | $0 | $0 | $0 | $0 | $0 | -$620K | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $257K | $11.66M | $439K | $1.3M | $374K | $626K | $1.8M | $395K | $0 | $68.76M | $10.04M |
| Net Cash from Financing | $43.46M | $131.04M | $70.51M | $142.95M | $65.99M | $69.08M | $33.94M | $90.56M | -$278K | $68.76M | $10.04M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$28.91M | $75.17M | -$81.68M | $132.25M | -$6M | $18.13M | -$26.38M | $22.68M | -$24.48M | $56.59M | $1.97M |
| Supplementary Data | |||||||||||
| Operating Cash Flow | -$109.71M | -$123.06M | -$99.54M | -$57.36M | -$60.25M | -$40.31M | -$44.73M | -$40.54M | -$23.03M | -$11.97M | -$7.19M |
| Capital Expenditure | -$272K | -$1.24M | -$1.25M | -$3.34M | -$12.64M | -$1.38M | -$821K | -$2.32M | -$1.18M | -$201K | -$878K |
| Free Cash Flow | -$109.98M | -$124.31M | -$100.78M | -$60.7M | -$72.89M | -$41.7M | -$45.55M | -$42.86M | -$24.21M | -$12.17M | -$8.07M |
| Cash at Beginning | $170.55M | $95.39M | $177.07M | $44.82M | $50.81M | $32.69M | $58.59M | $35.91M | $60.39M | $3.8M | $1.83M |
| Cash at End | $141.65M | $170.55M | $95.39M | $177.07M | $44.82M | $50.81M | $32.2M | $58.59M | $35.91M | $60.39M | $3.8M |